Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to -$3.0 million.

  • Traws Pharma's Net Income towards Common Stockholders fell 11179.34% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year increase of 6841.91%. This contributed to the annual value of -$54.7 million for FY2024, which is 18854.76% down from last year.
  • Per Traws Pharma's latest filing, its Net Income towards Common Stockholders stood at -$3.0 million for Q3 2025, which was down 11179.34% from -$625000.0 recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Net Income towards Common Stockholders registered a high of $15.1 million during Q1 2025, and its lowest value of -$21.4 million during Q4 2024.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$4.5 million (2023), whereas its average is -$4.9 million.
  • In the last 5 years, Traws Pharma's Net Income towards Common Stockholders tumbled by 38003.14% in 2024 and then soared by 40268.91% in 2025.
  • Quarter analysis of 5 years shows Traws Pharma's Net Income towards Common Stockholders stood at -$3.8 million in 2021, then tumbled by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then plummeted by 380.03% to -$21.4 million in 2024, then skyrocketed by 85.83% to -$3.0 million in 2025.
  • Its last three reported values are -$3.0 million in Q3 2025, -$625000.0 for Q2 2025, and $15.1 million during Q1 2025.